Novo Nordisk Haemophilia A drug does well in Phase III trial

• Novo Nordisk (NYSE:NVO) "reports positive results" from the first Phase III trial of its N8-GP treatment for Haemophilia A.
• The study assessed the safety and efficacy of N8-GP when administered for prophylaxis and when given on-demand in patients who are aged 12 and above.
• Other than that, Novo provided no other information about the results. (PR)